Show simple item record

dc.contributor.authorRahman, Md Atiqur
dc.contributor.authorSalajegheh, Ali
dc.contributor.authorSmith, Robert Anthony
dc.contributor.authorLam, Alfred King-yin
dc.date.accessioned2017-05-03T14:42:16Z
dc.date.available2017-05-03T14:42:16Z
dc.date.issued2014
dc.identifier.issn1568-0096
dc.identifier.urihttp://hdl.handle.net/10072/65112
dc.description.abstractBRAF is a major oncoprotein and oncogenic mutations in BRAF are found in a significant number of cancers, including melanoma, thyroid cancer, colorectal cancer and others. Consequently, BRAF inhibitors have been developed as treatment options for cancers with BRAF mutations which have shown some success in improving patient outcomes in clinical trials. Development of resistance to BRAF kinase inhibitors is common, however, overcoming this resistance is an area of significant concern for clinicians, patients and researchers alike. In this review, we identify the mechanisms of BRAF kinase inhibitor resistance and discuss the implications for strategies to overcome this resistance in the context of new approaches such as multi-kinase targeted therapies and emerging RNA interference based technologies.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent429661 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherBentham Science
dc.publisher.placeNetherlands
dc.publisher.urihttp://www.ingentaconnect.com/content/ben/ccdt/2014/00000014/00000002/art00003
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom128
dc.relation.ispartofpageto143
dc.relation.ispartofissue2
dc.relation.ispartofjournalCurrent Cancer Drug Targets
dc.relation.ispartofvolume14
dc.rights.retentionY
dc.subject.fieldofresearchMedicinal and biomolecular chemistry
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchcode3404
dc.subject.fieldofresearchcode3211
dc.subject.fieldofresearchcode3214
dc.titleBRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medicine
gro.rights.copyright© 2014 Bentham Science Publishers. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal website for access to the definitive, published version.
gro.date.issued2015-02-03T03:03:01Z
gro.hasfulltextFull Text
gro.griffith.authorLam, Alfred K.
gro.griffith.authorAriana, Armin S.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record